ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
8.54
0.00 (-0.01%)
At close: Jun 29, 2026, 4:00 PM EDT
8.56
+0.02 (0.24%)
After-hours: Jun 29, 2026, 4:10 PM EDT
Company Description
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
ARS Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 159 |
| CEO | Richard Lowenthal |
Contact Details
Address: 11682 El Camino Real, Suite 300 San Diego, California 92130 United States | |
| Phone | 858 771 9307 |
| Website | ars-pharma.com |
Stock Details
| Ticker Symbol | SPRY |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001671858 |
| CUSIP Number | 82835W108 |
| ISIN Number | US82835W1080 |
| Employer ID | 81-1489190 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard E. Lowenthal M.B.A., M.S., MSMSEL | Co-Founder, Chief Executive Officer and Director |
| Dr. Sarina Tanimoto M.B.A., M.D. | Co-Founder and Chief Medical Officer |
| Justin Chakma | Chief Business Officer |
| Donn Casale | President |
| Dr. Robert Bell Ph.D. | Co-Founder and Chief Science Officer |
| Kathleen D. Scott CPA | Chief Financial Officer |
| Brian T. Dorsey M.S. | Chief Operating Officer |
| Alexander A. Fitzpatrick Esq. | Chief Legal Officer and Secretary |
| Daniel Relovsky | Senior Vice President of Marketing |
| Lynda Harris | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2026 | 8-K | Current Report |
| Jun 12, 2026 | 144 | Filing |
| Jun 12, 2026 | 144 | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | 10-Q | Quarterly Report |
| May 15, 2026 | 8-K | Current Report |
| May 13, 2026 | 8-K | Current Report |
| Apr 29, 2026 | ARS | Filing |
| Apr 29, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2026 | DEF 14A | Other definitive proxy statements |